Drug intelligence / Profile preview

CBX-880

Development stage: Preclinical
Lead developer: Crossbow Therapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

CBX-880 is an investigational T-cell receptor (TCR)-mimetic T-cell engager (TCE) developed using Crossbow Therapeutics' proprietary T-Bolt™ platform. It is designed to target an undisclosed peptide-HLA (pHLA) complex derived from a cancer-testis antigen presented on HLA-A*02:01, while simultaneously binding to CD3 on T cells to recruit and activate T cells against tumor cells. CBX-880 is being developed for the treatment of solid tumors, including squamous non-small-cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ovarian cancer, and esophageal cancer. The program is currently in the IND-enabling stage of development.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CBX-880.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CBX-880.

Explore the full profile